Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04754425 2026-02-06

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Phase 2 Terminated

11 enrolled

Genitourinary

Prostatic Neoplasms

NCT05366842 2026-01-30

Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care

Phase 2 Terminated

3 enrolled 5 charts

Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Genitourinary

Advanced and Metastatic Urothelial Cancer

NCT05067777 2025-12-15

mPROSTATE

Phase 2 Terminated

28 enrolled

Genitourinary

Prostatic Neoplasms

NCT02772562 2025-12-12

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

Phase 2 Terminated

33 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT04176497 2025-12-11

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Phase 2 Terminated

8 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT06818305 2025-12-11

EmFin-Nx

Phase 2 Terminated

10 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Renal Insufficiency, Chronic

NCT03274258 2025-12-03

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Phase 2 Terminated

10 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

51 enrolled

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT02316548 2025-11-20

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

Phase 2 Terminated

14 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Phase 2 Terminated

6 enrolled 11 charts

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04635059 2025-11-17

BLAST

Phase 2 Terminated

6 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Phase 2 Terminated

18 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03747419 2025-10-31

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2 Terminated

14 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms

NCT04586244 2025-10-30

Optimus

Phase 2 Terminated

30 enrolled 12 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Phase 2 Terminated

15 enrolled 10 charts

Genitourinary

Urinary Bladder Neoplasms

NCT04616547 2025-10-03

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Phase 2 Terminated

1 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 2 Terminated

23 enrolled 15 charts

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

13 enrolled

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04936230 2025-08-17

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Phase 2 Terminated

1 enrolled 1 chart

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Phase 2 Terminated

6 enrolled 10 charts

Genitourinary

Biochemically Recurrent Prostate Carcinoma

NCT05563272 2025-07-10

STARBURST

Phase 2 Terminated

11 enrolled

CNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT03432897 2025-07-08

337

Phase 2 Terminated

1 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT04102124 2025-06-24

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Phase 2 Terminated

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

18 enrolled

Genitourinary

ATM Gene Mutation

NCT05712174 2025-06-12

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Phase 2 Terminated

176 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 15 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT02446860 2025-06-06

ADAPTeR

Phase 2 Terminated

15 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Phase 2 Terminated

2 enrolled 12 charts

GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04294277 2025-04-18

PEGASUS

Phase 2 Terminated

2 enrolled 6 charts

Genitourinary

Carcinoma, Transitional Cell

NCT03764540 2025-04-13

CABPOSTAAT

Phase 2 Terminated

57 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

DICE

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NeuroPrevPTSD

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

PLUTO

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Tivozanib + Enzalutamide in Adv Prostate Cancer

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Tamarack

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

mPROSTATE

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

EmFin-Nx

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

NIRADO

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

BLAST

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Optimus

PAVO

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

PRESERVE3

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

STARBURST

337

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

ADAPTeR

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Afatinib in Advanced Refractory Urothelial Cancer

PEGASUS

CABPOSTAAT